Development of new non-peptide GPIIb-IIIa antagnosts, NSL-95315 and NSL-95317, isosteres of NSL-95300

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 16, 1997, Pages 2099-2104

  Asari, Tohru ^a   Ishikawa, Shigetaka ^a   Sasaki, Toshiki ^a   Katada, Jun ^a   Hayashi, Yoshio ^a   Harada, Takeo ^a   Yano, Mako ^a   Yasuda, Emiko ^a   Uno, Isao ^a   Ojima, Iwao ^b  

^a NIPPON STEEL CORPORATION   (Japan)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; NSL 95315; NSL 95317; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

EID: 0030739850     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00366-1     Document Type: Article

References (22)

1. Ruoslahti, E.; Pierschbacher, M. D. Science 1987, 238, 491.
2. (a) Weller, T.; Alig, L.; Hurzeler, M.; Muller, M.; Kouns, W. C.; Steiner, B. Drugs of the Future 1994, 19, 461.
3. (b) Cook, N. S.; Kottirsch, G.; Zerwes, H.-G. Drugs of the Future 1994, 19, 135.
4. Harada, T.; Katada, J.; Tachiki, A.; Asari, T.: Iijima, K.; Uno, I.; Ojima, I.; Hayashi, Y. Bioorg. Med. Chem. Lett. 1997, 7, 209.
5. (a) Spatola, A. In Chemistry and Biochemistry of Amino Acids, Peptides and Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; Vol. 7, pp 267.
6. (b) Martinez, J.; Bali, J.-P.; Rodriguez, M.; Castro, B.; Magous, R.; Laur, J.; Lignon, M.-F. J. Med. Chem. 1985, 28, 1874.
7. (c) Sasaki, Y.; Murphy, W. A.; Heiman, M. L.; Lance, V. A.; Coy, D. H. ibid. 1987, 30, 1162.
8. (d) Rodriguez, M.; Lignon, M.-F.; Galas, M.-C.; Fulcrand, P.; Mendre, C.; Aumelas, A; Laur, J.; Martinez, J. ibid. 1987, 30 , 1366.
9. (e) Hocart, S. J.; Murphy, W. A.; Coy, D. H. ibid. 1990, 33, 1954.
10. (f) Haffar, B. M.; Hocart, S. J.; Coy, D. H.; Mantey, S.; Chiang, H.-C.; Jensen, R. T. J. Biol. Chem. 1991, 266, 316.
11. (g) Meyer, J.-P.; Davis, P.; Lee, K. B.; Porreca, F.; Yamamura , H. I.; Hruby, V.J. J. Med. Chem. 1995, 38, 3462.
12. (a) Hann, M. M.; Sammes, P. G.; Kannewell, P. D.; Taylor, J. B. J. Chem. Soc., Chem. Commun. 1980, 234.
13. (b) Dickerson, R. E.; Geis, I. In The Structure and Action of Protein; Harper & Row: New York, Evanston, London, 1969; pp 13.
14. (c) Schulz, G. E.; Schirmer, R. H. In Principles of Protein Structure; Springer-Verlag: New York, Heidelberg, Berlin, 1979; pp 18.
15. (d) Sukumaran, D. K.; Prorok, M.; Lawrence, D. S. J. Am. Chem. Soc. 1991, 113, 706 and references cited therein.
16. (e) London, R. E.; Matwiyoff, N. A.; Stewart, J. M.; Cann, J., R. Biochemistry 1978, 17, 2277.
17. tert-Butyl 2,2-dimethylacetoacetate was synthesized from isobutyryl chloride in 3 steps (esterification with tert-butyl alcohol, aldol condensation with acetaldehyde, and Jones' oxidation).
18. Luche, J. L.; Rodrigues, H. L.; Crabbe, P. J. Chem. Soc., Chem. Commun. 1978, 14, 601.
19. 2 in methanol gave methyl piperidine-4-acetate.
20. Aldehyde (11) was prepared from isobutyryl chloride in 2 steps (esterification with tert-butyl alcohol and aldol condensation with ethyl formate).
21. 50 s determined as the concentration of compound required to achieve 50% inhibition.
22. 1H-NMR spectrum.